Analyses of the TCGA PanCancer Atlas Studies through cBioPortal31 revealed that ZNF768 gene is altered in 1.9% of tumors, with the highest incidence being observed in endometrial carcinomas (5.1%), melanoma (4.7%), invasive breast cancer carcinoma (4.3%), mature B-cell neoplasm (4.2%), and bladder urothelial carcinoma (4.1%) (Fig. 6A). This evidence concerns the gene ZNF768 and neoplasm of mature B-cells.